CancerLinQ LLC and Society of Gynecologic Oncology Partner to Improve Quality in Women’s Oncology Care

Leading Professional Society for Comprehensive Management of Gynecologic Cancers is the Latest Organization to Join CancerLinQ’s Growing Coalition

For immediate release

May 24, 2017

ASCO Contact:
Julianne Lee
(571) 483-1381
julianne.lee@asco.org

SGO Contact:
Elizabeth Edwards
(618) 795-4824
elizabeth.edwards@sgo.org

ALEXANDRIA, Va. -- CancerLinQ LLC and the Society of Gynecologic Oncology (SGO) announced today a partnership where the SGO will provide expert guidance and insight on the management of gynecologic cancers for the CancerLinQ® platform. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that is developing and operating CancerLinQ®, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.

“CancerLinQ is delighted to welcome the Society of Gynecologic Oncology to our growing community of committed, collaborative partners,” said CancerLinQ Chief Executive Officer Kevin Fitzpatrick. “SGO will provide expert thought leadership and guidance on the quality of women’s health care and will be an invaluable voice as the CancerLinQ initiative continues to grow and serve the entire oncology ecosystem.”

The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. With 2,000 members representing the entire gynecologic oncology team in the United States and abroad, SGO’s members include primarily gynecologic oncologists, as well as medical oncologists, pathologists, radiation oncologists,
hematologists, surgical oncologists, obstetrician/gynecologists, nurses, physician assistants, social workers, fellows-in-training, residents, and other allied health care professionals interested in the treatment and care of women’s cancer.

ASCO and the SGO have collaborated previously to improve the quality of women’s health care in issuing joint guidelines on the treatment of ovarian cancer. The two societies currently work to test gynecologic oncology measures in ASCO’s Quality Oncology Practice Initiative (QOPI®) program.

SGO representative Summer Dewdney, MD, Assistant Professor of Gynecologic Oncology at Rush University Medical Center in Chicago, will participate in the CancerLinQ Oncology Leadership Council, the official body of strategic advisors comprised of member representatives from CancerLinQ partner organizations and other CancerLinQ advisory groups. Through SGO’s commitment to promoting the highest quality of comprehensive clinical care through education and research, the society will provide their thought leadership to CancerLinQ as the multidisciplinary big data initiative accelerates its growth and evolution.

“I am excited to join and provide insight as a representative for SGO and gynecologic cancers on the CancerLinQ Oncology Leadership Council,” said Dr. Dewdney. “I look forward to improving the quality of comprehensive clinical care by offering a perspective from SGO.”

As an official CancerLinQ partnering organization, the SGO will have access to CancerLinQ Discovery™ -- anonymized, statistically de-identified, fit-for-purpose clinical data sets derived from the CancerLinQ platform to support hypothesis-based research. Physicians, researchers, and analysts with interests in the oncology field can submit requests to the CancerLinQ Discovery Research & Publications Committee for access to data sets to be used in creating new clinical knowledge for improving patient outcomes. The data sets are generated from the rapidly growing CancerLinQ database, which currently includes practices in 40 states and the District of Columbia.
The collaboration with the SGO is the latest in a series of partnerships that CancerLinQ LLC has entered with thought leaders from a variety of influential organizations, including government agencies, professional medical specialty societies, advocacy groups, and the life sciences community. To date, CancerLinQ LLC has publicly announced formal partnerships with the American Society of Radiation Oncology, American Academy of Physicians Assistants, Cancer Informatics for Cancer Centers, College of American Pathologists, Hematology/Oncology Pharmacy Association, Oncology Nursing Society, and AstraZeneca, which became the founding enterprise partner for CancerLinQ Discovery™ in November 2016. The goal of these strategic alliances is to create a multidisciplinary, networked coalition of committed leaders for expertise, guidance, and accelerated creation of new insights for the CancerLinQ platform that can improve quality, efficiency, and value for the entire cancer care delivery system.

CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.

CancerLinQ® and CancerLinQ Discovery™ are projects of CancerLinQ LLC. For more information on how to participate or collaborate with CancerLinQ, please visit CancerLinQ.org.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube. Cancer-related policy developments can be found at ascoaction.asco.org.

About CancerLinQ LLC

CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ® initiative. CancerLinQ is a health information technology platform aimed at enhancing and improving the understanding and treatment of
cancer. To learn more, visit www.cancerlinq.org.

About the Society of Gynecologic Oncology
The Society of Gynecologic Oncology (SGO) is a 501 © (6) national medical specialty organization of physicians and allied health care professionals who are trained in the comprehensive management of women with malignancies of the reproductive tract. Visit the SGO website, to learn more at https://www.sgo.org/.